Quantinuum (Nasdaq: QNT) reported Q2 2026 revenue of $8.0 million, up 279% from $2.1 million a year earlier, while GAAP net loss per Class A common share was $1.93 with no comparable prior-year EPS presented. Consolidated GAAP net loss widened sharply, largely because of equity compensation and other noncash or transaction-related charges, but adjusted losses also increased. Despite the quarterly revenue rebound, first-half revenue remained below the prior-year period, while IPO proceeds lifted cash to $2.1 billion.

Core earnings data

Revenue increased by $5.9 million year over year, while GAAP gross margin improved by 27.4 percentage points but remained negative. Adjusted gross margin stayed positive at 61.7%, only slightly below the prior-year quarter.

Expenses rose much faster than revenue. Reported research and development expense increased to $367.3 million from $39.7 million, while general and administrative expense reached $151.9 million compared with $6.1 million. Large equity-compensation charges associated with the reorganization contributed substantially to these reported increases.

GAAP EPS covers only June 5 through June 30, following the reorganization, and is based on the loss attributable to Quantinuum Inc.’s Class A shareholders. Adjusted EPS is calculated on a fully distributed basis for the full quarter, so the two measures use different periods and ownership bases.

Noncash reorganization charges drove the GAAP loss, but underlying losses also increased

The main adjustment between GAAP and non-GAAP results was $464.6 million of equity compensation and related employer taxes. Quantinuum also excluded a $47.6 million noncash warrant fair-value loss, $10.6 million of IPO readiness and transaction costs, and smaller asset-related charges when calculating adjusted results.

These adjustments reduced the reported $596.5 million consolidated loss to an adjusted net loss of $73.1 million. However, that adjusted loss was still wider than the prior-year loss of $49.9 million, while adjusted EBITDA loss increased by $24.9 million. The non-GAAP results therefore show that the deterioration was not solely an accounting effect.

A similar gap appeared in gross margin. Quantinuum added back $6.6 million of equity compensation and related taxes and $3.5 million of depreciation and amortization to move from a $5.2 million GAAP gross loss to $4.9 million of adjusted gross profit. This produced a negative GAAP margin but a 61.7% adjusted margin.

Q2 growth did not reverse first-half revenue volatility

Although Q2 revenue nearly quadrupled from a low prior-year base, revenue for the first six months of 2026 was $13.2 million, down approximately 37.5% from $21.2 million in the first half of 2025. Quantinuum said results at its early commercial stage can be affected by the timing of individual contracts.

This difference between the quarterly and year-to-date trends is important when evaluating the 279% headline growth rate. It indicates that contract timing can create substantial fluctuations between reporting periods even as the company builds its commercial pipeline.

Commercial partnerships and technology roadmap

Quantinuum announced a strategic partnership with Oracle to deploy its Helios system within Oracle Cloud Infrastructure as a service for hybrid quantum and AI workloads. It also established a framework with HPE for integrating quantum computing with high-performance computing and AI environments. The company did not disclose contract values or quantify the Q2 revenue contribution from either relationship.

On the technology side, Quantinuum reported near five-nines logical fidelity on Helios using a new quantum error-correction code family. Sol remains targeted for launch in 2027, with its trap chip undergoing product validation, while Apollo remains scheduled for 2029.

Nexus, the company’s cloud-based development platform, was being used by 180 organizations. Quantinuum also signed a joint development agreement with a global electronics manufacturer to support future system infrastructure and manufacturing and entered a letter of intent with the U.S. Department of Commerce’s CHIPS R&D Office concerning domestic trapped-ion supply chains.

Cash flow and balance sheet

Quantinuum provided cash-flow figures only for the six-month period, rather than Q2 separately. Operating cash outflow was $129.1 million in the first half of 2026, compared with $65.8 million a year earlier, while capital expenditures were $39.2 million versus $37.7 million. Combined operating cash use and capital expenditures were approximately $168.3 million.

Cash and cash equivalents increased to $2.11 billion at June 30 from $762.6 million at the end of 2025. The main source was the IPO, which raised $1.7 billion in gross proceeds; first-half net cash provided by financing activities was $1.51 billion. The larger cash balance gives Quantinuum capacity to fund its development roadmap, though operating cash use also increased materially.

FY2026 guidance

Quantinuum established its first formal guidance as a public company, projecting 2026 revenue of $28 million to $32 million. The release described this as an improved outlook but did not provide a previous numerical range, so the size of any increase cannot be measured from the supplied information.

With first-half revenue of $13.2 million, the range implies approximately $14.8 million to $18.8 million of revenue in the second half of 2026.

Recent insider transactions

The supplied insider dataset lists nine purchases at $60 per share on June 5, 2026, with an aggregate reported value of approximately $23.32 million, followed by a no-cost stock award in July. Its separate six-month summary reports zero purchases and sales, which conflicts with the detailed entries below; the dated records are therefore presented without drawing conclusions about insider sentiment.

Risks investors need to watch

• Operating losses remain large relative to revenue. Adjusted EBITDA loss exceeded Q2 revenue by more than eight times, and the adjusted loss widened despite the revenue increase.
• Contract timing can distort growth rates. Q2 revenue rose 279%, but first-half revenue declined, demonstrating the volatility associated with individual contracts at an early commercial stage.
• Commercialization remains dependent on future execution. Oracle and HPE expand Quantinuum’s potential distribution and integration channels, but no related contract values or revenue contributions were disclosed.
• The product roadmap extends over several years. Sol is planned for 2027 and Apollo for 2029, leaving execution, validation, manufacturing, and market-acceptance risks before those systems can contribute at scale.
• GAAP and adjusted profitability differ substantially. Large equity-compensation and other excluded charges make the choice of performance measure particularly important when assessing cost trends.

Summary

Quantinuum’s Q2 revenue accelerated from a small prior-year base, supported by continued commercial and technology development, but first-half revenue remained lower and both adjusted net loss and adjusted EBITDA loss widened. The IPO substantially strengthened liquidity, providing funding for the Helios, Sol, and Apollo roadmaps. The next key tests are whether contract activity can produce steadier revenue, whether the company can meet its first formal full-year guidance, and whether adjusted losses begin to stabilize as commercialization progresses.

Find out more